The FY2025 (Dec) proxy of Gilead Sciences names 10 peer companies for pay. Among Gilead Sciences and these peers, CEO pay was 4th highest of 9 and total shareholder return was 3rd highest of 9.
4th highest of 9in Gilead Sciences and its pay peers, FY2025 (Dec) by CEO pay:
$7.3M$36.7M
3rd highest of 9in Gilead Sciences and its pay peers, FY2025 (Dec) by total shareholder return:
$86$671
Pay peer group, FY2025 (Dec) proxy
| Eli Lilly & Co | ||
| Johnson & Johnson | ||
| AbbVie | ||
| Pfizer | ||
| Amgen | ||
| Bristol Myers Squibb | ||
| Merck & Co. | ||
| Regeneron Pharmaceuticals | ||
| Biogen | Not disclosed | Not disclosed |
| Vertex Pharmaceuticals Incorporated | Not disclosed | Not disclosed |
10 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.